About VPD-HLRI
The Victor Phillip Dahdaleh Heart and Lung Research Institute (VPD-HLRI) is a joint venture between Royal Papworth Hospital and the University of Cambridge.
Based on the Cambridge Biomedical Campus, the VPD-HLRI combines world-leading life science, translational research and clinical excellence.
By bringing together the NHS, academia, industry and charity, it has created a unique environment to deliver high-impact research tackling global cardiovascular and respiratory diseases - some of the world's biggest killers.
VPD-HLRI is next to Royal Papworth on the Cambridge Biomedical Campus, the largest biotech cluster outside the United States.
The near-400 researchers, scientists and clinicians based inside HLRI are united in their focus on prevention, early diagnosis and treatment of heart and lung diseases by creating, testing and delivering new treatments to tackle the biggest causes of premature death in the world all on one site.
Royal Papworth Charity contributed £5 million to support the build to ensure our patients have access to the world’s best treatment.
Unmet needDespite a growing awareness of risk factors, the prevalence of cardiovascular and lung disease is increasing. There are 27 million deaths caused by cardiovascular and lung diseases each year. |
Other funders include: The UK Research Partnership Investment Fund which contributed £30m; the University of Cambridge; the Wolfson Foundation; the British Heart Foundation which donated £10m; and £5m by the Cystic Fibrosis Trust for a Cystic Fibrosis Trust Innovation Hub.
VPD-HLRI in pictures
From construction in 2020 to the official opening by HRH Duchess of Gloucester in 2022, explore the VPD-HLRI in pictures.
